ReviewBiotechnology progress
Bioprocess engineering issues that would be faced in producing a DNA vaccine at up to 100 m3 fermentation scale for an influenza pandemic.
Review in Biotechnology progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- From Bioreactor to Bulk Rheology: Achieving Scalable Production of Highly Concentrated Circular DNA.Advanced materials (Deerfield Beach, Fla.) · 2024Article
- Advancements in the development of subunit influenza vaccines.Microbes and infection · 2015Review
- Current advancements and potential strategies in the development of MERS-CoV vaccines.Expert review of vaccines · 2014Review
- Biomaterials at the interface of nano- and micro-scale vector-cellular interactions in genetic vaccine design.Journal of materials chemistry. B · 2014Article
- Antibiotic-free production of a herpes simplex virus 2 DNA vaccine in a high yield cGMP process.Human vaccines & immunotherapeutics · 2013Article
- Review
- Generic plasmid DNA production platform incorporating low metabolic burden seed-stock and fed-batch fermentation processes.Biotechnology and bioengineering · 2009Article
- Rational vector design for efficient non-viral gene delivery: challenges facing the use of plasmid DNA.Molecular biotechnology · 2008Review
- The threat of avian influenza A (H5N1). Part IV: Development of vaccines.Medical microbiology and immunology · 2007Review
- Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production.Biotechnology advancesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The risk of a pandemic with a virulent form of influenza is acknowledged by the World Health Organization (WHO) and other agencies. Current vaccine production facilities would be unable to meet the global requirement for vaccine. As a possible supplement a DNA vaccine may be appropriate, and bioprocess engineering factors bearing on the use of existing biopharmaceutical and antibiotics plants to produce it are described. This approach addresses the uncertainty of timing of a pandemic that precludes purpose-built facilities. The strengths and weaknesses of alternative downstream processing routes are analyzed, and several gaps in public domain information are addressed. The conclusion is that such processing would be challenging but feasible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.